O-GlcNAcase targets pyruvate kinase M2 to regulate tumor growth Journal Article


Authors: Singh, J. P.; Qian, K.; Lee, J. S.; Zhou, J.; Han, X.; Zhang, B.; Ong, Q.; Ni, W.; Jiang, M.; Ruan, H. B.; Li, M. D.; Zhang, K.; Ding, Z.; Lee, P.; Singh, K.; Wu, J.; Herzog, R. I.; Kaech, S.; Wendel, H. G.; Yates, J. R. 3rd; Han, W.; Sherwin, R. S.; Nie, Y.; Yang, X.
Article Title: O-GlcNAcase targets pyruvate kinase M2 to regulate tumor growth
Abstract: Cancer cells are known to adopt aerobic glycolysis in order to fuel tumor growth, but the molecular basis of this metabolic shift remains largely undefined. O-GlcNAcase (OGA) is an enzyme harboring O-linked β-N-acetylglucosamine (O-GlcNAc) hydrolase and cryptic lysine acetyltransferase activities. Here, we report that OGA is upregulated in a wide range of human cancers and drives aerobic glycolysis and tumor growth by inhibiting pyruvate kinase M2 (PKM2). PKM2 is dynamically O-GlcNAcylated in response to changes in glucose availability. Under high glucose conditions, PKM2 is a target of OGA-associated acetyltransferase activity, which facilitates O-GlcNAcylation of PKM2 by O-GlcNAc transferase (OGT). O-GlcNAcylation inhibits PKM2 catalytic activity and thereby promotes aerobic glycolysis and tumor growth. These studies define a causative role for OGA in tumor progression and reveal PKM2 O-GlcNAcylation as a metabolic rheostat that mediates exquisite control of aerobic glycolysis. © 2019, The Author(s), under exclusive licence to Springer Nature Limited.
Keywords: signal transduction; controlled study; protein expression; unclassified drug; human cell; protein targeting; enzyme activity; proteomics; microarray analysis; upregulation; catalysis; tumor growth; genetic database; acylation; n acetylglucosamine; aerobic glycolysis; pyruvate kinase; pyruvate kinase m2; human; priority journal; article; hela cell line; acetylglucosaminidase; n acetylglucosamine transferase
Journal Title: Oncogene
Volume: 39
Issue: 3
ISSN: 0950-9232
Publisher: Nature Publishing Group  
Date Published: 2020-01-16
Start Page: 560
End Page: 573
Language: English
DOI: 10.1038/s41388-019-0975-3
PUBMED: 31501520
PROVIDER: scopus
PMCID: PMC7107572
DOI/URL:
Notes: Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Hans Guido Wendel
    102 Wendel